Jin Gyu Cheong

Jin Gyu Cheong

Auto-generated profile, based on publicly available information

Jin Gyu Cheong

Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 August 2023 in Cell
Verified
Journal Article
Closed access
JCJin-Gyu Cheong
Jin-Gyu Cheong
ARArjun Ravishankar
Arjun Ravishankar
SSSiddhartha Sharma
Siddhartha Sharma
CPChristopher N. Parkhurst
Christopher N. Parkhurst
SGSimon A. Grassmann
Simon A. Grassmann
SJSteven Z. Josefowicz
Steven Z. Josefowicz

9 May 2024 in Blood
Verified
Journal Article
Open access
PDF file
PQPamela Quaranta
Pamela Quaranta
LBLuca Basso-Ricci
Luca Basso-Ricci
RHRaisa Jofra Hernandez
Raisa Jofra Hernandez
GPGuido Pacini
Guido Pacini
MNMatteo Maria Naldini
Matteo Maria Naldini
SSSerena Scala
Serena Scala
In physiological conditions, few circulating hematopoietic stem/progenitor cells (cHSPCs) are present in the peripheral blood, but their contribution to human hematopoiesis remain unsolved. By integrating advanced immunophenotyping, single-cell transcriptional and functional profiling, and integration site (IS) clonal tracking, we unveiled the biological properties and the transcriptional features of human cHSPC subpopulations in relationship to their bone marrow (BM) counterpart. We found that cHSPCs reduced in cell count over aging and are enriched for primitive, lymphoid, and erythroid subpopulations, showing preactivated transcriptional and functional state. Moreover, cHSPCs have low expression of multiple BM-retention molecules but maintain their homing potential after xenotransplantation. By generating a comprehensive human organ-resident HSPC data set based on single-cell RNA sequencing data, we detected organ-specific seeding properties of the distinct trafficking HSPC subpopulations. Notably, circulating multi-lymphoid progenitors are primed for seeding the thymus and actively contribute to T-cell production. Human clonal tracking data from patients receiving gene therapy (GT) also showed that cHSPCs connect distant BM niches and participate in steady-state hematopoietic production, with primitive cHSPCs having the highest recirculation capability to travel in and out of the BM. Finally, in case of hematopoietic impairment, cHSPCs composition reflects the BM-HSPC content and might represent a biomarker of the BM state for clinical and research purposes. Overall, our comprehensive work unveiled fundamental insights into the in vivo dynamics of human HSPC trafficking and its role in sustaining hematopoietic homeostasis. GT patients’ clinical trials were registered at ClinicalTrials.gov (NCT01515462 and NCT03837483) and EudraCT (2009-017346-32 and 2018-003842-18).

21 March 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
ADAndrew W. Daman
Andrew W. Daman
AAAnthony Claude Antonelli
Anthony Claude Antonelli
GRGil Redelman-Sidi
Gil Redelman-Sidi
LPLucinda Paddock
Lucinda Paddock
JCJin Gyu Cheong
Jin Gyu Cheong
MGMichael S. Glickman
Michael S. Glickman
Summary: Mycobacterium bovis BCG is the vaccine against tuberculosis and an immunotherapy for bladder cancer. When administered intravenously, BCG reprograms bone marrow hematopoietic stem and progenitor cells (HSPCs), leading to heterologous protection against infections. Whether HSPC-reprogramming contributes to the anti-tumor effects of BCG administered into the bladder is unknown. We demonstrate that BCG administered in the bladder in both mice and humans reprograms HSPCs to amplify myelopoiesis and functionally enhance myeloid cell antigen presentation pathways. Reconstitution of naive mice with HSPCs from bladder BCG-treated mice enhances anti-tumor immunity and tumor control, increases intratumor dendritic cell infiltration, reprograms pro-tumorigenic neutrophils, and synergizes with checkpoint blockade. We conclude that bladder BCG acts systemically, reprogramming HSPC-encoded innate immunity, highlighting the broad potential of modulating HSPC phenotypes to improve tumor immunity. Graphical

17 April 2024 in Immunological Reviews
Verified
Journal Article
Closed access
ADAndrew W. Daman
Andrew W. Daman
JCJin Gyu Cheong
Jin Gyu Cheong
LBLaura Berneking
Laura Berneking
SJSteven Z. Josefowicz
Steven Z. Josefowicz